Lech Ignatowicz

We developed a new technology for enzymatic production of high quality, long and even functionalized DNA molecules, which will have a huge impact on industrial synthetic biology, precision diagnostics, therapeutics and nanotechnology. DNA oligonucleotides are commonly synthesized by solid phase, but after decades of fine-tuning and improvements in liquid handling, the upper limit of phosphoramidite-based oligo synthesis is now about 200-300 nucleotides, with further limitations in terms of purity and efficacy in presence of strong secondary structures or repeats. The advances and improvements in diagnostic and therapeutic systems based on nucleic acids are leading to a big and urgent need of highly pure and long DNA strands, and Moligo Technologies mission is to satisfy this necessity. In fact, thanks to our know-how, and to the capacity of experienced scientific and executive team, we are already able to synthesize, and very soon commercialize, single stranded oligonucleotides of thousands of bases with purity of about 99.9%.

We focus on development of rapid point-of-care diagnostics for infectious diesease detection as well as innovative reagents for diagnostic and therapeutic purposes. Our strength lies in the proprietary technologies for sample preparation, production of monoclonal antibodies targeted primarily to the carbohydrate antigens and improvement of existing technologies used in development of molecular diagnostics. Our expertise in the fields of chemistry and immunology enables us to generate a number of highly sensitive and avid monoclonal antibodies to be used in Tuberculosis diagnostics, as well as other highly pathogenic bacterial and viral diseases. We also produce a wide range of bacterial antigens or their functional analogs.

We developed a new technology for enzymatic production of high quality, long and even functionalized DNA molecules, which will have a huge impact on industrial synthetic biology, precision diagnostics, therapeutics and nanotechnology. DNA oligonucleotides are commonly synthesized by solid phase, but after decades of fine-tuning and improvements in liquid handling, the upper limit of phosphoramidite-based oligo synthesis is now about 200-300 nucleotides, with further limitations in terms of purity and efficacy in presence of strong secondary structures or repeats. The advances and improvements in diagnostic and therapeutic systems based on nucleic acids are leading to a big and urgent need of highly pure and long DNA strands, and Moligo Technologies mission is to satisfy this necessity. In fact, thanks to our know-how, and to the capacity of experienced scientific and executive team, we are already able to synthesize, and very soon commercialize, single stranded oligonucleotides of thousands of bases with purity of about 99.9%.

Molecular Attraction technology enable development of vector-diseases control and eradication strategies. We are a bio-attractant discovery company. We identify biological compounds which can change behaviour of vectors organisms like mosquitoes, flies or rodents. Molecular Attraction compounds includes: Volatile attractants Phagostimulants Pheromones Molecular Attraction is a biotechnology company anchored in high-end research stemming from Stockholm University. Our competence: Biochemical compound identification Insect behaviour Parasitic infections biochemistry and immunology

Nordic Science Capital is a fully private investment company. Our main interest is in the technologies which have strong scientific fundamentals, can be scaled, patented and applied to multiple areas. Scientific/academic founders with unorthodox background. Inception stage to Seed. Primarily in Nordics and CEE.

We focus on development of rapid point-of-care diagnostics for infectious diesease detection as well as innovative reagents for diagnostic and therapeutic purposes. Our strength lies in the proprietary technologies for sample preparation, production of monoclonal antibodies targeted primarily to the carbohydrate antigens and improvement of existing technologies used in development of molecular diagnostics. Our expertise in the fields of chemistry and immunology enables us to generate a number of highly sensitive and avid monoclonal antibodies to be used in Tuberculosis diagnostics, as well as other highly pathogenic bacterial and viral diseases. We also produce a wide range of bacterial antigens or their functional analogs.